BiotechTube
Trisk Bio

Trisk Bio

London, United Kingdom· Est.
triskbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Trisk Bio operates as a specialized contract development and manufacturing organization (CDMO) focused on the preclinical AAV vector space. The company offers fully scalable manufacturing processes, producing vectors from 1e13 vg for research up to 1e15 vg for NHP toxicology studies, alongside high-throughput process optimization and analytical development services. By providing these critical, early-stage manufacturing capabilities, Trisk Bio aims to de-risk and accelerate the preclinical pathway for gene therapy companies, particularly those targeting rare diseases. Its business model is service-based, positioning it as an enabler for the broader gene therapy sector rather than a therapeutic developer itself.

Rare Disease

Technology Platform

Scalable AAV manufacturing and process development platform utilizing high-throughput optimization for capsid/transgene combinations and analytical development for vector characterization.

Opportunities

The company operates in the high-growth gene therapy CDMO sector, specifically addressing the bottleneck of scalable preclinical manufacturing.
Its focus on NHP-grade material and process development positions it as a critical partner for biotechs advancing toward clinical trials.
The scalable process model offers a clear path to capturing larger, later-stage projects from successful clients.

Risk Factors

Key risks include intense competition in the preclinical CRO/CDMO space, dependency on the funding climate for early-stage biotechs, and operational risks associated with consistently delivering high-quality, high-titer AAV for diverse client constructs.
As a small, likely project-funded company, it also faces client concentration and financial sustainability risks.

Competitive Landscape

Trisk Bio competes with other specialized preclinical CDMOs/CROs (e.g., Vigene Biosciences, Cell and Gene Therapy Catapult's services) and the early-stage service arms of larger CDMOs (e.g., Catalent, Lonza's early development services). Its differentiation hinges on a dedicated focus on scalable AAV processes from the outset, high-throughput optimization, and a tailored approach for rare disease gene therapy developers.

More companies in United Kingdom →